Value Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at 9th Annual World ADC. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either by forming supplier collaborations or by acquiring specialised facilities […]

How Forward Thinking and New Approaches Will Drive Up Efficiency

Charlie Johnson, CEO of  biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps. Charlie Johnson – CEO, ADC Bio As an advanced manufacturing concept, integrated bioconjugation is highly promising – and is now under development – with the […]

ADC Bio Secures Additional Equity Round Investment

Posted on November 14, 2018 ADC Biotechnology (ADC Bio), announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales and Downing LLP. The finance will be deployed to ensure the achievement of specific business goals […]

Downing FOUR VCT invests £1.14 million in ADC Biotechnology Ltd

Investment from Downing FOUR VCT (Healthcare and General share classes) advised by BioScience Managers Limited Funds used to progress development of Antibody Drug Conjugate (ADCs) technology Downing FOUR VCT is targeting dividends of at least 4% p.a. (of net assets) from the fourth year onwards * London, UK, 24 April 2018 – London-based investment management […]